Idera Pharmaceuticals (IDRA -2.4%) announces final results from a Phase 1/2 clinical trial, ILLUMINATE-204, evaluating Toll-like receptor 9 (TLR9) agonist tilsotolimod, combined with Bristol-Myers Squibb’s (BMY -1.4%) Yervoy (ipilimumab), in metastatic melanoma patients.
Archive | Clinical Trials
Idera’s tilsotolimod shows positive effect in mid-stage melanoma study
Posted in Melanoma News, Health Professionals, Clinical Trials
On-off dosing of cancer drugs does not help melanoma patients
Drugs that home in on and block cell growth signals can dramatically shrink tumors, but all too often the cancer comes back. An attention-grabbing mouse study 7 years ago suggested these targeted drugs would work better at shrinking melanoma tumors if cancer patients got a break from their medicine every few weeks.
Posted in Melanoma News, Health Professionals, Clinical Trials
Alternative pembrolizumab dosing schedule safe, effective in metastatic melanoma
Source: Healio, April 2020 An alternative pembrolizumab dosing regimen of 400 mg every 6 weeks appeared safe and effective for patients with metastatic melanoma, according to first clinical outcomes data from KEYNOTE-555 cohort B presented at the virtual American Association for Cancer Research Annual Meeting. “Pembrolizumab [Keytruda, Merck] is approved globally in multiple cancer indications […]
Posted in Melanoma News, Health Professionals, Clinical Trials
Phase 2 Trial of Probody-Opdivo Combo Expanding in Advanced Cancers
An ongoing Phase 1/2a trial exploring a type of engineered antibody — the anti-CTLA-4 probody BMS-986249 by CytomX Therapeutics — alone and in combination with Opdivo (nivolumab) in treating advanced solid tumors is expanding to include people with melanoma.
Posted in Melanoma News, Health Professionals, Clinical Trials
